Based on the Cellect Biotechnology Ltd stock forecast from 0 analysts, the average analyst target price for Cellect Biotechnology Ltd is not available over the next 12 months. Cellect Biotechnology Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Cellect Biotechnology Ltd is Neutral, which is based on 1 positive signals and 1 negative signals. At the last closing, Cellect Biotechnology Ltd’s stock price was USD 0.00. Cellect Biotechnology Ltd’s stock price has changed by 0% over the past week, 0% over the past month and 0% over the last year.
No recent analyst target price found for Cellect Biotechnology Ltd
No recent average analyst rating found for Cellect Biotechnology Ltd
Company Overview Cellect Biotechnology Ltd
As of October 28, 2021, Cellect Biotechnology Ltd. was acquired by Quoin Pharmaceuticals, Inc., in a reverse merger transaction. Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. The company develops ApoTainer, a kit for hematopoietic stem cell transplantation procedures. It has collaborations with the denovoMATRIX group of the Technische Universität Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; Cell2in Inc. to conduct scientific evaluations combining ApoGraft with Cell2in's identification technology FreSHtracer, which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state; and XNK therapeutics to focus on the development of cell-based therapeutics from NK cells. The company was formerly known as Cellect Biomed Ltd. and changed its name to Cellect Biotechnology Ltd. in July 2016. Cellect Biotechnology Ltd. was incorporated in 1986 and is headquartered in Kfar Saba, Israel. Read Less
As of October 28, 2021, Cellect Biotechnology Ltd. was acquired by Quoin Pharmaceuticals, Inc., in a reverse merger transaction. Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enha...Read More
Frequently Asked Questions About Cellect Biotechnology Ltd (APOP) Stock
Stock Target Advisor's fundamental analysis for Cellect Biotechnology Ltd's stock is Neutral.
Unfortunately we do not have enough data on APOP's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on APOP's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on APOP's stock to indicate if its overvalued.
The last closing price of APOP's stock was USD 0.00.
The most recent market capitalization for APOP is USD 0.01B.
Unfortunately we do not have enough analyst data on APOP's stock to indicate whether its price will go up or not.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for APOP !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
